Strimvelis for Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID)
Quick answer: Strimvelis is used for Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) as part of a gene therapy (ex vivo autologous cd34+ cells transduced with retroviral vector encoding ada) treatment regimen. Autologous gene therapy that introduces a functional ADA gene into the patient's hematopoietic stem cells to restore adenosine deaminase activity The specific dosing for Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) is determined by your prescriber based on individual factors.
Why is Strimvelis used for Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID)?
Strimvelis belongs to the Gene therapy (ex vivo autologous CD34+ cells transduced with retroviral vector encoding ADA) class. Autologous gene therapy that introduces a functional ADA gene into the patient's hematopoietic stem cells to restore adenosine deaminase activity This action makes it useful for treating or managing Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Strimvelis is the right choice for a specific patient depends on the type and severity of Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID)
Common adult dosing range: Single intravenous infusion of autologous CD34+ cells. The actual dose for Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Strimvelis medicine page.
What to expect
Strimvelis treatment for Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID)
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Strimvelis is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Gene therapy (ex vivo autologous CD34+ cells transduced with retroviral vector encoding ADA) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Strimvelis
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Strimvelis full prescribing information · All Gene therapy (ex vivo autologous CD34+ cells transduced with retroviral vector encoding ADA) alternatives
Frequently asked questions
How effective is Strimvelis for Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID)?
Effectiveness varies by individual response, dose, and severity. Strimvelis is one of several treatment options for Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), supported by clinical evidence within the gene therapy (ex vivo autologous cd34+ cells transduced with retroviral vector encoding ada) class. Discuss expected response with your prescriber.
How long do I need to take Strimvelis for Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID)?
Treatment duration depends on the nature of Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Strimvelis when used for Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID)?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Strimvelis for Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID)?
Yes. Multiple medicines and non-drug options exist for Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID). Alternatives within the gene therapy (ex vivo autologous cd34+ cells transduced with retroviral vector encoding ada) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.